IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC
Status:
Recruiting
Trial end date:
2025-06-04
Target enrollment:
Participant gender:
Summary
The study will be conducted in women with advanced (stage IIIa-IV) ovarian cancer of the
histologic subtype high grade serous carcinoma (HGSOC) who are going through a diagnostic
laparoscopy. They will recieve treatment with a study agent for 10-14 days before surgery.
They will be allocated to different study groups according to the diagnostic evaluation
performed as standard of care at the department. The study is randomized and unblinded.
The primary investigational agents are:
1. Metformin tablets, 850 mg x 2 orally.
2. Acetylsalicylic acid tablets, 160 mg x1 orally
3. Olaparib capsules, 300 mg x 2 orally
4. Letrozol tablets, 2.5 mg x 1 orally